FDA gives tentative nod to Zydus Cadila for generic Tradjenta  

Press enter to search
Close search
Open Menu

FDA gives tentative nod to Zydus Cadila for generic Tradjenta  

By Sandra Levy - 10/30/2020

Adult patients with Type 2 diabetes will soon have a new generic treatment.

The Food and Drug Administration has given tentative approval for Zydus Cadila’s linagliptin tablets in a dosage strength of 5 mg.

The medication is the generic of Boehringer Ingelheim’s Tradjenta.

Linagliptin tablets are used as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.

The medication will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

 

Related Topics